Skip Navigation



JAC Advance Access published online on November 18, 2002
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkf214
© 2002 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/6/1011    most recent
dkf214v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ziglam, H. M.
Right arrow Articles by Finch, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ziglam, H. M.
Right arrow Articles by Finch, R. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2002 The British Society for Antimicrobial Chemotherapy

Original Paper

Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy

Hisham M. Ziglam 1, David R. Baldwin 1, Ian Daniels 1, Jenny M. Andrew 2, Roger G. Finch 1*

1 Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
2 Antibiotic Research Laboratory, City Hospital NHS Trust, Dudley Road, Birmingham B18 7QH, UK

* Corresponding author. E-mail: roger.finch{at}nottingham.ac.uk.

Received 8 April 2002 ; revised 2 August 2002 ; accepted 15 August 2002

Abstract

The concentrations of rifampicin in epithelial lining fluid (ELF), human alveolar macrophages (AM), bronchial mucosal biopsies and serum were measured after a single oral dose of 600 mg rifampicin from 15 patients undergoing fibre-optic bronchoscopy. The samples of ELF, AM, the bronchial mucosal biopsies and serum were obtained ~2-5 h after dosing. The mean concentrations (mean ± standard error) were 5.25 mg/L (±0.67) in ELF, 7.93 mg/kg (±1.61) in bronchial biopsies, 15.48 mg/L (±1.41) in serum and 251.8 mg/L (±65.92) in alveolar macrophages. These site concentrations exceeded the MIC90 for common respiratory pathogens including Mycobacterium tuberculosis and support the observed clinical efficacy of rifampicin in the treatment of a wide range of respiratory tract infections.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Y. Yuhas, E. Berent, R. Cohen, and S. Ashkenazi
Roles of NF-{kappa}B Activation and Peroxisome Proliferator-Activated Receptor Gamma Inhibition in the Effect of Rifampin on Inducible Nitric Oxide Synthase Transcription in Human Lung Epithelial Cells
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1539 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Laohavaleeson, P. R. Tessier, and D. P. Nicolau
Pharmacodynamic Characterization of Ceftobiprole in Experimental Pneumonia Caused by Phenotypically Diverse Staphylococcus aureus Strains
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2389 - 2394.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Kiem and J. J. Schentag
Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.